Floatz logo

Treg Cells

Chronic Myeloid Leukemia

Masonic Cancer Center, University of MinnesotaCell therapyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
81/ 100

Competitive context

85 Active assets in the Chronic Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
City of Hope Medical Center
Phase 3BBB
Nilotinib
Novartis Pharmaceuticals
Phase 4BBB
Romidepsin
Center for International Blood and Marrow Transplant Research
Phase 2BBB
Sargramostim
Virginia Commonwealth University
Phase 2BBB
Therapeutic Allogeneic Lymphocytes
University of Chicago
Phase 2BBB

View all 50 →

Same molecule, other indications

Treg Cells is also rated in:

myeloproliferative neoplasmDormant
B
Indicative ·
62 / 100
View asset →
acute lymphoblastic leukemiaDormant
B
Indicative ·
58 / 100
View asset →
Chronic Myeloproliferative DiseaseDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →